Use of microvesicles in analyzing nucleic acid profiles

• US 10,407,728 B2
• Filed: 07/06/2015
• Issued: 09/10/2019
• Est. Priority Date: 09/09/2009
• Status: Active Grant

• Current Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Inventors: Noerholm, Mikkel, Skog, Johan Karl Olov, Breakefield, Xandra O., Carter, Bob
• Primary Examiner(s): Hibbert, Catherine S
• Application Number:
  US14/792,212
• Publication Number:
  US 20160002736A1
• Time in Patent Office: 1,527 Days
• Field of Search: None
• CPC Class Codes: C12Q 1/6806 Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay C12Q1/6804 takes precedence
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2563/161 Vesicles, e.g. liposome
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 33/57407 Specifically defined cancers

Abstract

The invention concerns gene signatures obtained from microvesicles and a method of applying these gene signatures in helping to determine a biological condition. The determination of a biological condition may aid, for example, the diagnosis, prognosis, and therapy treatment selection for disease in a subject.

Claims

1. A method of treating glioblastoma in a subject, comprising:

a. extracting RNA transcripts from at least one microvesicle isolated from a biological sample from the subject;

b. measuring the expression level of the genes consisting of TMSL3, GNG11, A_24_P530977, B2M, RGS10, GPX1, RPS29, ENST00000357697, LOC390427, SLITRK4, LGAL27, ENST00000325151, RALGDS, MESP1, SYMPK, C17orf74, J03651, FZD9, AL566332, ZNF784, SERPINB1, FOXD3, ENST00000325371, THC2504037, RNF151, ENST00000360514, BAX, POLD1, RKHD1, LGR4, CV575560 in the extracted RNA transcripts;

c. creating a genetic profile of the subject based on the measured expression level of each gene;

d. comparing the genetic profile to a reference profile using clustering analysis or principle component analysis; and

e. treating glioblastoma in the subject having a statistically significant difference in the genetic profile compared to the reference profile.

2. The method of claim 1, wherein the biological sample is selected from the group consisting of blood, serum, plasma and urine.

3. The method of claim 1, wherein measuring expression comprises determination of the presence or absence of the RNA transcribed from the gene, determination of the quantitative level of the RNA transcribed, or a combination thereof.

4. The method of claim 1, wherein measuring expression level is by microarray analysis, reverse transcription PCR, quantitative PCR, or a combination thereof.

5. The method of claim 1, wherein the at least one microvesicle originates from a specific cell type.

6. The method of claim 1, wherein the subject is a human subject.

7. The method of claim 6, wherein the human subject is a glioblastoma patient.